To the Editor:
Prognostic Scores in Pulmonary Embolism
To the Editor:
We reviewed the article published in CHEST (April 2012) by Lankeit et al 1 during our monthly journal club. The authors have done an impressive job of assessing the performance of the two prognostic models for pulmonary embolism in predicting shortterm mortality: the European Society of Cardiology (ESC) model and the simplifi ed Pulmonary Embolism Severity Index.
While reviewing this article, we came across a few contradicting data. In the "Results" section, while reporting secondary outcomes, the authors mentioned that secondary end points occurred in 1.8% (95% CI, 0.2-3.9%) of the simplifi ed Pulmonary Embolism Severity Index low-risk strata and 5.8% (95% CI, 2.6-9.0%) of the ESC low-risk strata with a difference of 4.0% points (95% CI, 0.2-7.8).
However, in Table 4 , which is the corresponding table for both primary and secondary outcome, the percentage of patients who met secondary end points in low-risk ESC model strata is reported as 2.4% (95% CI, 0.3-4.5), which is different from the percentage reported in the text. To evaluate this discrepancy, we took the liberty of editing Table 4 to make it more illustrative ( Table 1 ) . In this table, we can clearly see that if we accept the secondary end point rate for the ESC model as such, the total number of secondary end points is 21, which is the reported total number of secondary end points in the study. But, if we accept the secondary end point rate of 5.8% for low-risk ESC model strata, then the total number of patients meeting this end point for low-risk ESC model strata would be 12 and total number of secondary end point events for the ESC model would be 28 (low-risk strata 5 12 and elevated-risk strata 5 16) ( Table 2 ) , which is incorrect according to the reported events in the study.
In the absence of the raw data, we are not in the position to make the fi nal evaluation of this discrepancy. Therefore, it would be helpful if the authors could elaborate on these data and indicate the effects on secondary end points if it was incorrectly reported .
Probiotics in Critically Ill Patients More Data Are Needed

To the Editor:
We read with great interest the article by Barraud et al 1 in this issue of CHEST (see page 646) discussing the effects of probiotics on mortality in critically ill adult patients. We congratulate them and applaud their work, but we feel a couple of issues must be addressed.
First, in the "Selection of Studies" section the authors declared that randomized controlled trials were potentially evaluated if they enrolled critically ill adult patients admitted into an ICU and compared the administration of probiotics (and/or prebiotics or synbiotics) and control (placebo or other), and that the articles must also have reported on ICU or hospital mortality. Was that the inclusion/exclusion criteria of their report? If so, why did they not include the trial conducted by Giamarellos-Bourboulis et al? 2 The authors should have given a more detailed description of the inclusion/exclusion criteria.
Second, the meta-analysis also evaluated the effects of probiotics on secondary outcomes, including all-cause hospital mortality, incidence of ICU-acquired infection, incidence of diarrhea, duration of mechanical ventilation, and ICU and hospital length of stay. In fact, these results are not conclusive because the examination of the effects of probiotics on these end points was not adequately powered. They were not regarded as the primary outcome but were the only clinically signifi cant end points consistently reported in some of the studies included in this meta-analysis. More data are needed to clarify these questions in essence instead of inform . 
Wan-Jie Gu
